BRCA1 and cancer: Although we demonstrated high sensitivity (> 80%) and positive predictive value (PPV; 25%), two symptomatic interval cancers occurred, and 69% of detected cancers were stage III to IV.16 This annual screening interval has been associated with a poor 10-year survival rate of 36% in BRCA1/2 carriers.21